Orexo AB
STO:ORX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Orexo AB
Total Receivables
Orexo AB
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Orexo AB
STO:ORX
|
Total Receivables
kr237.4m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
|
Camurus AB
STO:CAMX
|
Total Receivables
kr443.2m
|
CAGR 3-Years
27%
|
CAGR 5-Years
38%
|
CAGR 10-Years
41%
|
|
|
E
|
Enzymatica AB (publ)
STO:ENZY
|
Total Receivables
kr13m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
2%
|
|
|
S
|
Swedencare AB (publ)
STO:SECARE
|
Total Receivables
kr441.9m
|
CAGR 3-Years
16%
|
CAGR 5-Years
54%
|
CAGR 10-Years
40%
|
|
|
I
|
Infant Bacterial Therapeutics AB
STO:IBT B
|
Total Receivables
kr2.8m
|
CAGR 3-Years
24%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
I
|
InDex Pharmaceuticals Holding AB
STO:FLERIE
|
Total Receivables
kr180.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Orexo AB
Glance View
Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. The company is headquartered in Uppsala, Uppsala and currently employs 121 full-time employees. The company went IPO on 2005-11-09. The company focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The firm has four commercialized products, several projects developed in partnership, as well as three development programs. The firm's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The firm operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
See Also
What is Orexo AB's Total Receivables?
Total Receivables
237.4m
SEK
Based on the financial report for Dec 31, 2025, Orexo AB's Total Receivables amounts to 237.4m SEK.
What is Orexo AB's Total Receivables growth rate?
Total Receivables CAGR 10Y
3%
Over the last year, the Total Receivables growth was -4%. The average annual Total Receivables growth rates for Orexo AB have been -4% over the past three years , 4% over the past five years , and 3% over the past ten years .
